MedTrace Logo

A Study Of IMM47 In Subjects With Advanced Solid Tumors

NCT05985083 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-10-04

No results posted yet for this study

Summary

This is a first-in-human (FIH), open-label, multi-center, phase I study to evaluate the safety, tolerance, pharmacokinetics (PK), immunogenicity, preliminary anti-tumor activity, pharmacodynamics, and biomarker activity of IMM47 monotherapy in subjects with advanced solid tumors.

Conditions

Interventions

DRUG

IMM47

IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.

Sponsors & Collaborators

  • IQVIA RDS Inc.

    collaborator INDUSTRY

  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

    lead OTHER

Principal Investigators

  • Jim Coward, A/Prof · Icon Cancer Centre South Brisbane, QLD

  • Charlotte Lemech, Dr · Scientia Clinical Research Ltd, NSW

  • Megan Crumbaker, Dr · Macquarie University Clinical Trials Unit (MQ CTU)

  • David Martin, Dr · John Flynn Private Hospital, QLD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-18
Primary Completion
2024-12-26
Completion
2025-01-23

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05985083 on ClinicalTrials.gov